Innovative cellular and stem cell approaches are transforming treatments across cancer and transplantation. UCLA researchers developed AlloCAR70-NKT, an off-the-shelf immunotherapy targeting metastatic renal cell carcinoma with dual tumor and microenvironment targeting capabilities, presenting a scalable alternative to custom therapies. Complementing this, studies on regulatory and virus-specific T cell therapies illustrate progressive strategies to enhance graft survival and disease control in transplantation settings.